The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Oncology in Pharmaceuticals: Gene therapy for cancers. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Gene therapy for cancers is a key innovation area in oncology
Gene therapy modifies an individual’s genes for the treatment of a disease. It works by replacing a disease-causing gene with its healthy copy, or suppressing a disease-causing gene by silencing it. It can also include the introduction of exogenous nucleic acid sequences to modulate gene expression. Gene modified cell-therapies, such as CAR-T and TCR, have established themselves as a new generation of therapies against cancer.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of gene therapy for cancers.
Key players in gene therapy for cancers – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to gene therapy for cancers
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Pfizer||226||Unlock Company Profile|
|Idera Pharmaceuticals||201||Unlock Company Profile|
|Ionis Pharmaceuticals||127||Unlock Company Profile|
|Mologen||117||Unlock Company Profile|
|Curevac||116||Unlock Company Profile|
|F. Hoffmann-La Roche||97||Unlock Company Profile|
|Nitto Denko||91||Unlock Company Profile|
|EnGeneIC||78||Unlock Company Profile|
|OncoTherapy Science||74||Unlock Company Profile|
|SBI Holdings||73||Unlock Company Profile|
|Otsuka Holdings||73||Unlock Company Profile|
|Novo Nordisk Foundation||72||Unlock Company Profile|
|Thermo Fisher Scientific||69||Unlock Company Profile|
|Alnylam Pharmaceuticals||59||Unlock Company Profile|
|GSK||54||Unlock Company Profile|
|Adhera Therapeutics||53||Unlock Company Profile|
|Zoetis||51||Unlock Company Profile|
|Dynavax Technologies||46||Unlock Company Profile|
|Kirin Holdings||45||Unlock Company Profile|
|InDex Pharmaceuticals Holding||45||Unlock Company Profile|
|Moderna||44||Unlock Company Profile|
|Gradalis||44||Unlock Company Profile|
|Centre National de la Recherche Scientifique||43||Unlock Company Profile|
|TargImmune Therapeutics||42||Unlock Company Profile|
|AdiuTide Pharmaceuticals||42||Unlock Company Profile|
|Arrowhead Pharmaceuticals||38||Unlock Company Profile|
|Changchun Huapu Biotechnology||38||Unlock Company Profile|
|Daiichi Sankyo||36||Unlock Company Profile|
|Exicure||36||Unlock Company Profile|
|OPKO Health||36||Unlock Company Profile|
|Amgen||35||Unlock Company Profile|
|Sanofi||35||Unlock Company Profile|
|Massachusetts General Hospital||34||Unlock Company Profile|
|MiNA (Holdings)||33||Unlock Company Profile|
|Regulus Therapeutics||33||Unlock Company Profile|
|Memorial Sloan Kettering Cancer Center||32||Unlock Company Profile|
|InteRNA Technologies||30||Unlock Company Profile|
|Biogenera||30||Unlock Company Profile|
|Sarepta Therapeutics||29||Unlock Company Profile|
|Codiak BioSciences||28||Unlock Company Profile|
|City of Hope||27||Unlock Company Profile|
|Ministry of Trade and Industry, Singapore||27||Unlock Company Profile|
|Regeneron Pharmaceuticals||26||Unlock Company Profile|
|Editas Medicine||26||Unlock Company Profile|
|PT Soho Global Health Tbk||26||Unlock Company Profile|
|Wave Life Sciences||26||Unlock Company Profile|
|Soluventis Nanotherapeutics||25||Unlock Company Profile|
|Onxeo||25||Unlock Company Profile|
|Bio-Path Holdings||24||Unlock Company Profile|
|Yuhan||22||Unlock Company Profile|
Source: GlobalData Patent Analytics
Pfizer is one of the leading patent filers for gene therapy for cancers. Pfizer discovers, develops, manufactures, and commercialises biopharmaceuticals. The company offers products to treat various conditions across cardiovascular, metabolic, pain, cancer, inflammation, immune disorders, and rare diseases. In terms of application diversity, Cytlimic is the top company, followed by Tallac Therapeutics and EMulate Therapeutics. By means of geographic reach, Regulus Therapeutics holds the top position. Otsuka and Phigenix stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.